Annual report pursuant to Section 13 and 15(d)

ACQUISITION OF CUREDM (Tables)

v3.19.1
ACQUISITION OF CUREDM (Tables)
12 Months Ended
Dec. 31, 2018
Acquisition Of Curedm  
Schedule of consideration

A summary of consideration is as follows:

 

25,000,000 shares of the Company’s common stock $ 1,250,000
22,741,140 contingency shares of the Company’s common stock  
     
Total consideration $ 1,250,000

 

The following summarizes the current estimates of fair value of assets acquired and liabilities assumed:

 

Assets acquired:    
Cash $ 3,592
Property and equipment   273
Goodwill   1,176,220
Intangibles   234,122
Liabilities assumed:    
Accounts payable and accrued expenses   (164,207)
Net assets acquired $ 1,250,000
Schedule of pro forma results

This pro forma financial information is based on historical results of operations, adjusted for the allocation of the purchase price and other acquisition accounting adjustments, and is not indicative of the results that may have been achieved had the companies been combined as of the first day of the period presented.

 

      For the year ended December 31,  
      2018       2017  
Total revenues   $ 31,273     $ 31,263  
Net loss     (3,601,217 )     (2,086,490 )
Basic and diluted net earnings per common share   $ (0.04 )   $ (0.03 )